We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Effects of Linezolid and Vancomycin on Inflammation and Cellular Signaling Vents

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00811980
First Posted: December 19, 2008
Last Update Posted: November 24, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Pfizer
Information provided by (Responsible Party):
University of Utah
December 17, 2008
December 19, 2008
November 24, 2011
January 2009
June 2010   (Final data collection date for primary outcome measure)
IL-6 [ Time Frame: 12 Months ]
Measurement of IL-6 release in response to MRSA.
Not Provided
Complete list of historical versions of study NCT00811980 on ClinicalTrials.gov Archive Site
MCP-1 [ Time Frame: 12 Months ]
Measurement of MCP-1 release in response to MRSA.
Not Provided
Not Provided
Not Provided
 
The Effects of Linezolid and Vancomycin on Inflammation and Cellular Signaling Vents
The Effects of Linezolid and Vancomycin on Inflammation and Cellular Signaling Vents
We will determine if linezolid inhibits cellular activation and production of pro-inflammatory cytokines, providing mechanistic rationale for its clinical efficacy and the justification for further investigations in S. Aureus sepsis.
Not Provided
Observational
Time Perspective: Prospective
Not Provided
Retention:   Samples Without DNA
Description:
Whole blood
Non-Probability Sample
Healthy subjects who consent to donate blood.
Sepsis
Drug: Linezolid or Vancomycin
Whole blood samples from healthy subjects will be incubated with MRSA bacterium or bacterial toxins in the presence and absence of either linezolid or vancomycin. Final concentrations will mimic physiologic conditions. Platelets and leukocytes will be isolated and assayed for the presence of absence of activation and pre-mRNA splicing.
Other Name: Zyvox
Heathy Subjects
Intervention: Drug: Linezolid or Vancomycin
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
60
June 2010
June 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Healthy, taking no medications, and not recently hospitalized

Exclusion Criteria:

  • Infection (active)
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Yes
Contact information is only displayed when the study is recruiting subjects
Not Provided
United States
 
NCT00811980
00392
Pfizer GA5951WK
No
Not Provided
Not Provided
University of Utah
University of Utah
Pfizer
Principal Investigator: Guy Zimmerman, MD University of Utah
University of Utah
November 2011